

**POWER OF ATTORNEY
and
CORRESPONDENCE ADDRESS
INDICATION FORM**

Application Number	10/564,123
Filing Date	1/6/06
First Named Inventor	Sato et al.
Title	NOVEL CHEMICAL COMPOUNDS
Art Unit	1624
Examiner Name	E. Leeser
Attorney Docket Number	TC00003US

I hereby revoke all previous powers of attorney given in the above-identified application.

I hereby appoint:

Practitioners associated with the Customer Number:

23347

OR

Practitioner(s) named below:

Name	Registration Number

as my/our attorney(s) or agent(s) to prosecute the application identified above, and to transact all business in the United States Patent and Trademark Office connected therewith.

Please recognize or change the correspondence address for the above-identified application to:

The address associated with the above-mentioned Customer Number:

OR

The address associated with Customer Number:

OR

Firm or Individual Name

Address

City

State

Zip

Country

Telephone

Email

I am the:

Applicant/Inventor.

Assignee of record of the entire interest. See 37 CFR 3.71.
Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96).

SIGNATURE of Applicant or Assignee of Record

Signature	<i>Robert H. Brink</i>	Date	<i>10 Month 2008</i>
Name	Robert H. Brink	Telephone	919-483-3323
Title and Company	Patent Counsel		

NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple

*Total of _____ forms are submitted.

This collection of information is required by 37 CFR 1.31, 1.32 and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending on the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

CERTIFICATE UNDER 37 C.F.R. §3.73(b)

Applicant: Hideyuki SATO et al.
 Appln No.: 10/564,123 Filed: 1/06/06
For: NOVEL CHEMICAL COMPOUNDS

SmithKline Beecham Corporation. **Corporation**
 (Name of Assignee) (Type of Assignee, e.g. corporation, partnership, university, etc.)

certifies that it is the assignee of the entire right, title and interest in the patent application identified above by virtue of either:

A. An assignment from the inventor(s) of the patent application identified above. The assignment was recorded on 5/23/06 in the Patent and Trademark Office at Reel 017671, Frame 0045, or for which a copy thereof is attached.

B. A chain of title from the inventor(s), of the patent application identified above, to the current assignee as shown below:

1. From: Inventors To: MitoKor
 The document was recorded in the Patent and Trademark Office at Reel xxx, Frame xxx, or for which a copy thereof is attached.

2. From: MitoKor To: SmithKline Beecham Corporation.
 The document was recorded in the Patent and Trademark Office at Reel xxx, Frame xxx, or for which a copy thereof is attached.

Additional documents in the chain of title are listed here:

The undersigned has reviewed all the documents in the chain of title of the patent application identified above and, to the best of undersigned's knowledge and belief, title is in the assignee identified above.

The undersigned (whose title is given below) is empowered to act on behalf of the assignee.

I hereby declare that all statements made herein of my own knowledge are true, and that all statements made on information and belief are believed to be true; and further, that these statements are made with the knowledge that willful false statements, and the like so made, are punishable by fine or imprisonment, or both, under Section 1001, Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Date: 10 March 2008
 SmithKline Beecham Corporation
 D/b/a GlaxoSmithKline.
 Corporate Intellectual Property
 Five Moore Drive, P.O. Box 13398
 Research Triangle Park, NC 27709
 Telephone No.: (919) 483-2370
 Facsimile No.: (919) 483-7988

Signature: Robert H. Brink
 By: Robert H. Brink
 Title: Attorney (resolution attached)

COMMONWEALTH OF PENNSYLVANIA

DEPARTMENT OF STATE

APRIL 05, 2001

TO ALL WHOM THESE PRESENTS SHALL COME, GREETING:

SMITHKLINE BEECHAM CORPORATION

I, Kim Pizzingrilli, Secretary of the Commonwealth of Pennsylvania do hereby certify that the foregoing and annexed is a true and correct photocopy of Articles of Merger restating the Articles of Incorporation in their entirety

which appear of record in this department



IN TESTIMONY WHEREOF, I have hereunto set my hand and caused the Seal of the Secretary's Office to be affixed, the day and year above written.

A handwritten signature in black ink that reads "Kim Pizzingrilli".

Secretary of the Commonwealth


DPOS

200124-955

MAR 30 2001

Microfilm Number _____

Filed with the Department of State on _____

Entity Number 333095


Secretary of the Commonwealth JK

ARTICLES OF MERGER-DOMESTIC BUSINESS CORPORATION

DCR:15-172 (Rev. 9/93)

In compliance with the requirements of 15 Pa.C.S. § 1924 (relating to articles of merger or consolidation), the undersigned business corporations, desiring to effect a merger, hereby state that:

SmithKline Beecham Corporation

1. The name of the corporation surviving the merger: _____

2. (Check and complete one of the following):

The surviving corporation is a domestic business corporation and the (a) address of its current registered office in this Commonwealth or (b) name of its commercial registered office provider and the county of venue is (the Department is hereby authorized to correct the following information to conform to the records of this Department):

(a) One Franklin Plaza, 200 North 16th Street, Philadelphia, PA 19102 Phila.
Number and Street City State Zip County

(b) c/o: Name of Commercial Registered Office Provider County

For a corporation represented by a commercial registered office provider, the county in (b) shall be deemed the county in which the corporation is located for venue and official publication purposes.

The surviving corporation is a qualified foreign business corporation incorporated under the laws of _____ and the (a) address of its current registered office in this Commonwealth or (b) name of its commercial registered office provider and the county of venue is (the Department is hereby authorized to correct the following information to conform to the records of this Department):

(a) Number and Street City State Zip County

(b) c/o: Name of Commercial Registered Office Provider County

For a corporation represented by a commercial registered office provider, the county in (b) shall be deemed the county in which the corporation is located for venue and official publication purposes.

The surviving corporation is a nonqualified foreign business corporation incorporated under the laws of _____ and the address of its principal office under the laws of such nonresident jurisdiction is:

Number and Street City State Zip

3. The name and the address of the registered office in this Commonwealth or name of its commercial registered office provider and the county of venue of each other domestic business corporation and qualified foreign business corporation which is a party to the plan of merger are as follows:

Name of Corporation	Address or Registered Office or Name of Commercial Registered Office Provider	County
Glaxo Wellcome Inc.	CT Corporation System	Philadelphia

200124-956

DSCB:15-1924 (Rev 90)-2

4. (Check, and if appropriate complete, one of the following):

 The plan of merger shall be effective upon filing these Articles of Merger in the Department of State. The plan of merger shall be effective on: March 31, 2001 at 11:30 p.m.
Date Hour

5. The manner in which the plan of merger was adopted by each domestic corporation is as follows:

Name of Corporation

Manner of Adoption

SmithKline Beecham CorporationAdopted by the directors and shareholders
pursuant to 15 Pa.C.S. § 1924(a).

6. (Strike out this paragraph if no foreign corporation is a party to the merger). The plan was authorized, adopted or approved, as the case may be, by the foreign business corporation (or each of the foreign business corporations) party to the plan in accordance with the laws of the jurisdiction in which it is incorporated.

7. (Check, and if appropriate complete, one of the following):

 The plan of merger is set forth in full in Exhibit A attached hereto and made a part hereof. Pursuant to 15 Pa.C.S. § 1901 (relating to omission of certain provisions from filed plans) the provisions, if any, of the plan of merger that amend or constitute the operative Articles of Incorporation of the surviving corporation as in effect subsequent to the effective date of the plan are set forth in full in Exhibit A attached hereto and made a part hereof. The full text of the plan of merger is on file at the principal place of business of the surviving corporation, the address of which is:

Number and Street _____ City _____ State _____ Zip _____ County _____

IN TESTIMONY WHEREOF, the undersigned corporation or each undersigned corporation has caused these Articles of Merger to be signed by a duly authorized officer thereof this _____ day of March, 2001.SMITHKLINE BEECHAM CORPORATION

(Name of Corporation)

BY: Donald F. Parman

(Signature)

TITLE: Donald F. Parman, SecretaryGLAXO WELLCOME INC.

(Name of Corporation)

BY: Paul A. Holcombe, Jr.

(Signature)

TITLE: Paul A. Holcombe, Jr., Secretary

Power of Attorney

BY THIS POWER OF ATTORNEY given this 22 day of November two thousand and seven GLAXO GROUP LIMITED, a company incorporated in England and Wales (Registration No. 305979) and having its registered office at Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex, UB6 0NN, England (hereinafter called "the Company"), HEREBY appoints all and any of its Directors, Secretary and Assistant Secretary for the time being, and SHERRY M. KNOWLES, ROBERT H. BRINK, MARCUS J. W. DALTON, HUGH B. DAWSON, PETER I. DOLTON, WENDY A. FILLER, THEODORE R. FURMAN, PETER J. GIDDINGS, EDWARD R. GIMMI, CHARLES M. KINZIG, HELEN K. QUILLIN, MARY E. McCARTHY, JEFFREY A. SUTTON, ARTHUR W. R. TYRRELL, STEPHEN VENETIANER and SUSAN M. WHITE jointly and severally to be its true and lawful agents and attorneys (hereinafter called "the Attorneys," and each an "Attorney") on behalf and in the name of the Company or otherwise to do, perform, exercise or execute or concur with any other person or persons in doing, performing or exercising in or for any country or countries or jurisdiction in any part of the world all or any of the following powers, acts, deeds and things in connection with: letters patent, including extensions thereto (including supplementary protection certificates and the like); utility models; copyrights; trademark registrations; trademarks; trade names; trade dress; logos; design rights; designs and all rights analogous thereto and all applications therefor and any other forms whatsoever of intellectual property rights; including know-how, all of which are hereinafter called "Intellectual Property Rights", that is to say:

1. In any country or countries or jurisdiction in any part of the world to make application or cause application to be made for the grant or issue or transfer to the Company or registration in its name of Intellectual Property Rights and to take all steps necessary for the same to be prosecuted, maintained, withdrawn, renewed, enforced, defended or extended.
2. As the act and deed of the Company to sign, seal, deliver and execute all or any assignments or assurances, licences to the Company of or under any Intellectual Property Rights or the right to and interest in any inventions to be the subject of Intellectual Property Rights for the purpose of fully and effectually vesting and transferring the same in and to the Company.
3. As the act and deed of the Company to sign and execute all or any assignments and acceptances of the transfer or assignment of such rights, and also any licences, sub-licences and consents from the Company of or under any Intellectual Property Rights or the right to and interest in any invention to be the subject of Intellectual Property Rights, for the purpose of fully and effectually vesting transferring or granting the same in and to any entity, whether in the United Kingdom or elsewhere, in so far as such documents can be executed without the Company's seal being affixed thereto. For purposes of this Power of Attorney, the terms "entity" means, and includes, any person, firm or company or group of persons or unincorporated body.
4. To give undertakings or assurances to third parties and to any Trademark Registry or official intellectual property agency or governmental department or otherwise responsible for the registration or protection of trademarks, trade names, trade dress, logos, design rights or designs for the purpose of best protecting or ensuring the co-existence of the Company's rights to trademarks, trade names, trade dress, logos, design rights or designs.
5. To commence, prosecute and defend any proceedings or applications whether judicial or extra judicial relating to Intellectual Property Rights and to maintain, withdraw or settle the same.
6. For and in connection with any Intellectual Property Rights to sign, seal, deliver and execute any Power of Attorney or other deed or document authorising any agent,

including trademark and patent agents and attorneys, to act on behalf of the Company.

To apply for the registration, amendment or cancellation of user rights in respect of any trademark or trade name.

To act in regard to all official communications which may now or hereafter be addressed to the Attorneys relating to Intellectual Property Rights or the renewal thereof in such manner that the Attorneys may be recognised as the authorised agent(s) of the Company in all proceedings in relation thereto.

9. For all or any of the purposes contained herein as the act and deed of the Company to sign, seal, deliver, execute and do all such documents, deeds, agreements, instruments and to do such acts as shall be requisite or may be deemed proper for or in relation to the said purposes.

It is hereby agreed that:

(a) this power of attorney shall remain in force until 31 December 2009 or (in respect of any Attorney) until his or her employment by the GlaxoSmithKline group of companies ceases, or until revocation by the Company, whichever first occurs; and


(b) in respect of any Attorney this power of attorney shall supersede and revoke with effect from the day and year first before written any power of attorney granted by the Company in favour of that Attorney covering all or some of the authorities herein contained.

AND THE COMPANY HEREBY RATIFIES and confirms and agrees to ratify and confirm all and whatsoever the Attorneys or any person, persons, firm or company appointed by them shall lawfully do or have done by virtue of the authorities herein contained.


AND THE COMPANY HEREBY DECLARES that all instruments executed under and by virtue of this Power shall be as valid and effectual as if sealed by the Common Seal of the Company.

IN WITNESS whereof **GLAXO GROUP LIMITED** has caused its Common Seal to be hereunto affixed the day and year first before written.

The COMMON SEAL of
GLAXO GROUP LIMITED
was hereto affixed in the presence of:)))



Paul Williamson
For and on behalf of
Edinburgh Pharmaceutical Industries Limited
Corporate Director



V.A. Whyte
Assistant Secretary

CERTIFIED TRUE COPY



Paul Williamson
For and on behalf of
Edinburgh Pharmaceutical Industries Limited
Corporate Director

